Pfizer Falls On Disappointing Breast Cancer PALLAS Study
May 29, 2020 at 18:07 PM EDT
Following an analysis, the independent data monitoring committee of the PALLAS study determined the trial is unlikely to show significant improvement in the primary endpoint of invasive disease-free survival.